Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Hudson |
RCV000224975 | SCV000281767 | likely pathogenic | not provided | 2016-05-12 | criteria provided, single submitter | research | |
Institute for Medical Genetics and Human Genetics, |
RCV002287395 | SCV002578164 | uncertain significance | Mega-corpus-callosum syndrome with cerebellar hypoplasia and cortical malformations | 2022-09-27 | criteria provided, single submitter | clinical testing | |
Institute for Clinical Genetics, |
RCV000224975 | SCV004026168 | uncertain significance | not provided | 2022-09-09 | criteria provided, single submitter | clinical testing | PM2_SUP, PP2 |
Labcorp Genetics |
RCV000224975 | SCV005837866 | uncertain significance | not provided | 2024-10-31 | criteria provided, single submitter | clinical testing | This sequence change replaces serine, which is neutral and polar, with leucine, which is neutral and non-polar, at codon 93 of the MAST1 protein (p.Ser93Leu). This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individual(s) with clinical features of MAST1-related conditions (PMID: 28554332). ClinVar contains an entry for this variant (Variation ID: 235895). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be disruptive. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |